Omeros Corporation (OMER) 11.10 $OMER
Omeros to Present at the 2016 Wedbush PacGrow Healthcare Conference
BusinessWire - Fri Aug 12, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2016 Wedbush PacGrow Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, August 17, 2016, at 9:10 a.m. EDT.
OMER: 11.10 (+0.34)
Omeros Announces Pricing of Public Offering of Common Stock
PR Newswire - Thu Aug 11, 9:49AM CDT
Omeros Corporation (NASDAQ: OMER) announced today the pricing of a $40 million underwritten public offering of its common stock at a price to the public of $11.50 per share, before deducting underwriting discounts and commission and other estimated offering expenses. The offering is expected to close on or about August 16, 2016, subject to the satisfaction of customary closing conditions.
OMER: 11.10 (+0.34)
Omeros Announces Public Offering of Common Stock
PR Newswire - Wed Aug 10, 3:01PM CDT
Omeros Corporation (NASDAQ: OMER) today announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co., as the sole underwriter, in a registered underwritten public offering.
OMER: 11.10 (+0.34)
Omeros' Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy in Paroxysmal Nocturnal Hemoglobinuria Model
BusinessWire - Wed Aug 10, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program. OMS906 is Omeros' lead antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3). In a well-established animal model associated with paroxysmal nocturnal hemoglobinuria (PNH), OMS906 significantly improved the survival of red blood cells when compared to control-treated animals and to animals treated with a complement component 5 (C5) inhibitor.
OMER: 11.10 (+0.34)
Omeros Corporation Reports Second Quarter 2016 Financial Results
BusinessWire - Tue Aug 09, 3:02PM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the second quarter of 2016, which include:
OMER: 11.10 (+0.34)
Medical Product Stocks' Earnings on Aug 9: PEN, STE & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:21AM CDT
We have already seen how the results so far have demonstrated a definite improvement from what we had experienced in the last couple of quarters.
NH: 12.52 (+0.05), STE: 71.00 (+0.89), EGRX: 60.34 (+1.32), PEN: 70.63 (+0.61), OMER: 11.10 (+0.34)
Omeros Corporation to Announce Second Quarter 2016 Financial Results on August 9, 2016
BusinessWire - Thu Aug 04, 8:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its second quarter 2016 financial results for the period ended June 30, 2016, on Tuesday, August 9, 2016, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results.
OMER: 11.10 (+0.34)
Omeros' Lead MASP-3 Inhibitor OMS906 Demonstrates Blockade of the Alternative Pathway of Complement System
BusinessWire - Thu Aug 04, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program. OMS906 is Omeros' lead antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the protein activator of the alternative pathway of complement (APC). OMS906 significantly reduced both incidence and severity of disease in a well-established animal model of arthritis mediated by the APC.
OMER: 11.10 (+0.34)
Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency
PR Newswire - Thu Jul 28, 8:27AM CDT
Omeros Corporation (NASDAQ: OMER) today announced that it has received scientific advice from the European Medicines Agency (EMA) in connection with the company's OMS721 Phase 3 program for the treatment of atypical hemolytic uremic syndrome (aHUS). Based on this EMA advice, the company plans to run the same, single Phase 3 clinical program to support OMS721 marketing approval applications in both the U.S. and in the European Union for the treatment of aHUS. OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies (TMAs), including aHUS and hematopoietic stem cell transplant-related (HSCT) TMAs, and for the treatment of complement-related renal diseases. Omeros plans to commercialize OMS721 initially for administration as a subcutaneous injection.
OMER: 11.10 (+0.34)
The Sub $1 Stock in the $800 Billion Cigarette Industry the Tobacco Giants Need to Stay Relevant
ACCESSWIRE - Mon May 23, 6:00AM CDT
WINDSOR, ON / ACCESSWIRE / May 23, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to bring to investors' attention how one little-known company, 22nd Century Group (NYSE MKT: XXII), has developed a revolutionary combustible cigarette that could give smokers exactly what they have been seeking, and drastically change the tobacco industry in the process.
RAI: 50.69 (+0.94), PM: 101.77 (+1.15), BTI: 129.19 (+3.88), XXII: 1.05 (+0.02), MO: 66.88 (+0.56), ARDM: 4.65 (unch), OMER: 11.10 (+0.34)
Omeros Announces Debt Financing Transaction for $20 Million in Additional Funds
BusinessWire - Tue May 17, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) (the "Company" today announced that it has entered into an amendment to its existing credit facility with Oxford Finance LLC ("Oxford" and East West Bank ("East West" to provide the Company with an additional $20 million in unrestricted cash by funding the remaining tranches of the facility. Omeros will issue warrants to the lenders, exercisable for seven years for up to 100,602 shares of the Company's common stock at an exercise price per share of $9.94, the closing price of the Company's stock on May 16, 2016. All loan payments will be interest-only until August 1, 2017. The final payment fee rate on the $20 million borrowed will increase from 5.25% to 6.25%, reflecting the accelerated draw-down of these additional funds. Omeros expects funding will occur on May 18, 2016.
OMER: 11.10 (+0.34)
Omeros reports 1Q loss
Automated Insights - Tue May 10, 6:26AM CDT
SEATTLE (AP) _ Omeros Corporation (OMER) on Tuesday reported a loss of $20.5 million in its first quarter.
OMER: 11.10 (+0.34)
Omeros Corporation Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 6:20AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the first quarter of 2016, which include:
OMER: 11.10 (+0.34)
Omeros Corporation Announces Exclusive Middle East Distribution Agreement for OMIDRIA(R)
BusinessWire - Tue May 10, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced entry into an exclusive supply and distribution agreement for the sale of OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% in the Kingdom of Saudi Arabia, the United Arab Emirates and other countries in the Middle East with ITROM Trading Drug Store (ITROM). ITROM is Dubai-based and an internationally recognized pharmaceutical marketing and distribution company specializing in ophthalmology. Under the agreement, ITROM will be responsible for obtaining marketing authorizations for OMIDRIA within the licensed territory and for marketing, selling and distributing product supplied by Omeros. Existing ophthalmology medical sales representatives employed by ITROM are expected to be reinforced with additional medical sales representatives that will be dedicated to OMIDRIA.
OMER: 11.10 (+0.34)
Omeros Corporation to Announce First Quarter 2016 Financial Results on May 10, 2016
BusinessWire - Wed May 04, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its first quarter 2016 financial results for the period ended March 31, 2016, on Tuesday, May 10, 2016, before the market opens. Omeros management will host a conference call and webcast that day at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) to discuss the financial results.
OMER: 11.10 (+0.34)
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.96 (unch), CBMG: 13.94 (-0.55), OCAT: 8.47 (+0.01), ZBH: 129.40 (+1.05), PFE: 34.77 (+0.09), LLY: 76.85 (-0.38), GSK: 44.26 (+1.28), GLPG: 54.35 (-0.05), AXSM: 7.27 (+0.02), OMER: 11.10 (+0.34), CANF: 2.36 (-0.11), AST: 2.96 (+0.14), AKTX: 9.10 (-0.20)
Omeros Corporation Announces Independent Studies with OMIDRIA(R) to Be Presented at Upcoming Ophthalmology Congresses
BusinessWire - Tue Apr 26, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that new research related to the clinical utility of OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% and the importance of preempting intraoperative miosis and inflammation during cataract surgery will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting in Seattle, Washington, May 1 - 5, 2016, and the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans, Louisiana, May 6 - 10, 2016. Presentations will address the beneficial effects demonstrated in case-controlled studies of OMIDRIA on complication rates, on use of pupil-expanding devices, on surgical times and on postoperative visual acuity.
OMER: 11.10 (+0.34)
Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases
BusinessWire - Wed Apr 20, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced initiation of patient dosing in its OMS721 Phase 2 program in corticosteroid-dependent renal diseases. The Phase 2 clinical trial of OMS721, the company's lead mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor being developed for complement-related diseases, is evaluating the effects of OMS721 on kidney function in patients with corticosteroid-dependent renal diseases. This new trial expands the company's MASP platform, which includes an OMS721 Phase 3 program in progress for the treatment of atypical hemolytic uremic syndrome (aHUS) as well as an ongoing Phase 2 program of OMS721 for the treatment of other thrombotic microangiopathies (TMAs).
OMER: 11.10 (+0.34)
Restless Legs Syndrome Pipeline Market 2016 Review Research
PR Newswire - Mon Apr 11, 7:30AM CDT
New market research titled "Restless Legs Syndrome - Pipeline Review, H1 2016" is a report that provides an overview of the Restless Legs Syndrome's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
OMER: 11.10 (+0.34)
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 2.35 (-0.02), OMER: 11.10 (+0.34), ATHX: 1.91 (-0.03), KPTI: 10.62 (-0.48), CUR: 0.25 (-0.02)
Omeros to Present at the 2016 Wedbush PacGrow Healthcare Conference
BusinessWire - Fri Aug 12, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2016 Wedbush PacGrow Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, August 17, 2016, at 9:10 a.m. EDT.
OMER: 11.10 (+0.34)
Omeros Announces Pricing of Public Offering of Common Stock
PR Newswire - Thu Aug 11, 9:49AM CDT
Omeros Corporation (NASDAQ: OMER) announced today the pricing of a $40 million underwritten public offering of its common stock at a price to the public of $11.50 per share, before deducting underwriting discounts and commission and other estimated offering expenses. The offering is expected to close on or about August 16, 2016, subject to the satisfaction of customary closing conditions.
OMER: 11.10 (+0.34)
Omeros Announces Public Offering of Common Stock
PR Newswire - Wed Aug 10, 3:01PM CDT
Omeros Corporation (NASDAQ: OMER) today announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co., as the sole underwriter, in a registered underwritten public offering.
OMER: 11.10 (+0.34)
Omeros' Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy in Paroxysmal Nocturnal Hemoglobinuria Model
BusinessWire - Wed Aug 10, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program. OMS906 is Omeros' lead antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3). In a well-established animal model associated with paroxysmal nocturnal hemoglobinuria (PNH), OMS906 significantly improved the survival of red blood cells when compared to control-treated animals and to animals treated with a complement component 5 (C5) inhibitor.
OMER: 11.10 (+0.34)
Omeros Corporation Reports Second Quarter 2016 Financial Results
BusinessWire - Tue Aug 09, 3:02PM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the second quarter of 2016, which include:
OMER: 11.10 (+0.34)
Medical Product Stocks' Earnings on Aug 9: PEN, STE & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:21AM CDT
We have already seen how the results so far have demonstrated a definite improvement from what we had experienced in the last couple of quarters.
NH: 12.52 (+0.05), STE: 71.00 (+0.89), EGRX: 60.34 (+1.32), PEN: 70.63 (+0.61), OMER: 11.10 (+0.34)
Omeros Corporation to Announce Second Quarter 2016 Financial Results on August 9, 2016
BusinessWire - Thu Aug 04, 8:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its second quarter 2016 financial results for the period ended June 30, 2016, on Tuesday, August 9, 2016, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results.
OMER: 11.10 (+0.34)
Omeros' Lead MASP-3 Inhibitor OMS906 Demonstrates Blockade of the Alternative Pathway of Complement System
BusinessWire - Thu Aug 04, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program. OMS906 is Omeros' lead antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the protein activator of the alternative pathway of complement (APC). OMS906 significantly reduced both incidence and severity of disease in a well-established animal model of arthritis mediated by the APC.
OMER: 11.10 (+0.34)
Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency
PR Newswire - Thu Jul 28, 8:27AM CDT
Omeros Corporation (NASDAQ: OMER) today announced that it has received scientific advice from the European Medicines Agency (EMA) in connection with the company's OMS721 Phase 3 program for the treatment of atypical hemolytic uremic syndrome (aHUS). Based on this EMA advice, the company plans to run the same, single Phase 3 clinical program to support OMS721 marketing approval applications in both the U.S. and in the European Union for the treatment of aHUS. OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies (TMAs), including aHUS and hematopoietic stem cell transplant-related (HSCT) TMAs, and for the treatment of complement-related renal diseases. Omeros plans to commercialize OMS721 initially for administration as a subcutaneous injection.
OMER: 11.10 (+0.34)
The Sub $1 Stock in the $800 Billion Cigarette Industry the Tobacco Giants Need to Stay Relevant
ACCESSWIRE - Mon May 23, 6:00AM CDT
WINDSOR, ON / ACCESSWIRE / May 23, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to bring to investors' attention how one little-known company, 22nd Century Group (NYSE MKT: XXII), has developed a revolutionary combustible cigarette that could give smokers exactly what they have been seeking, and drastically change the tobacco industry in the process. RAI: 50.69 (+0.94), PM: 101.77 (+1.15), BTI: 129.19 (+3.88), XXII: 1.05 (+0.02), MO: 66.88 (+0.56), ARDM: 4.65 (unch), OMER: 11.10 (+0.34)
Omeros Announces Debt Financing Transaction for $20 Million in Additional Funds
BusinessWire - Tue May 17, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) (the "Company"
today announced that it has entered into an amendment to its existing credit facility with Oxford Finance LLC ("Oxford" and East West Bank ("East West" to provide the Company with an additional $20 million in unrestricted cash by funding the remaining tranches of the facility. Omeros will issue warrants to the lenders, exercisable for seven years for up to 100,602 shares of the Company's common stock at an exercise price per share of $9.94, the closing price of the Company's stock on May 16, 2016. All loan payments will be interest-only until August 1, 2017. The final payment fee rate on the $20 million borrowed will increase from 5.25% to 6.25%, reflecting the accelerated draw-down of these additional funds. Omeros expects funding will occur on May 18, 2016. OMER: 11.10 (+0.34)
Omeros reports 1Q loss
Automated Insights - Tue May 10, 6:26AM CDT
SEATTLE (AP) _ Omeros Corporation (OMER) on Tuesday reported a loss of $20.5 million in its first quarter.
OMER: 11.10 (+0.34)
Omeros Corporation Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 6:20AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the first quarter of 2016, which include:
OMER: 11.10 (+0.34)
Omeros Corporation Announces Exclusive Middle East Distribution Agreement for OMIDRIA(R)
BusinessWire - Tue May 10, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced entry into an exclusive supply and distribution agreement for the sale of OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% in the Kingdom of Saudi Arabia, the United Arab Emirates and other countries in the Middle East with ITROM Trading Drug Store (ITROM). ITROM is Dubai-based and an internationally recognized pharmaceutical marketing and distribution company specializing in ophthalmology. Under the agreement, ITROM will be responsible for obtaining marketing authorizations for OMIDRIA within the licensed territory and for marketing, selling and distributing product supplied by Omeros. Existing ophthalmology medical sales representatives employed by ITROM are expected to be reinforced with additional medical sales representatives that will be dedicated to OMIDRIA.
OMER: 11.10 (+0.34)
Omeros Corporation to Announce First Quarter 2016 Financial Results on May 10, 2016
BusinessWire - Wed May 04, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its first quarter 2016 financial results for the period ended March 31, 2016, on Tuesday, May 10, 2016, before the market opens. Omeros management will host a conference call and webcast that day at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) to discuss the financial results.
OMER: 11.10 (+0.34)
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.96 (unch), CBMG: 13.94 (-0.55), OCAT: 8.47 (+0.01), ZBH: 129.40 (+1.05), PFE: 34.77 (+0.09), LLY: 76.85 (-0.38), GSK: 44.26 (+1.28), GLPG: 54.35 (-0.05), AXSM: 7.27 (+0.02), OMER: 11.10 (+0.34), CANF: 2.36 (-0.11), AST: 2.96 (+0.14), AKTX: 9.10 (-0.20)
Omeros Corporation Announces Independent Studies with OMIDRIA(R) to Be Presented at Upcoming Ophthalmology Congresses
BusinessWire - Tue Apr 26, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that new research related to the clinical utility of OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% and the importance of preempting intraoperative miosis and inflammation during cataract surgery will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting in Seattle, Washington, May 1 - 5, 2016, and the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans, Louisiana, May 6 - 10, 2016. Presentations will address the beneficial effects demonstrated in case-controlled studies of OMIDRIA on complication rates, on use of pupil-expanding devices, on surgical times and on postoperative visual acuity.
OMER: 11.10 (+0.34)
Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases
BusinessWire - Wed Apr 20, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced initiation of patient dosing in its OMS721 Phase 2 program in corticosteroid-dependent renal diseases. The Phase 2 clinical trial of OMS721, the company's lead mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor being developed for complement-related diseases, is evaluating the effects of OMS721 on kidney function in patients with corticosteroid-dependent renal diseases. This new trial expands the company's MASP platform, which includes an OMS721 Phase 3 program in progress for the treatment of atypical hemolytic uremic syndrome (aHUS) as well as an ongoing Phase 2 program of OMS721 for the treatment of other thrombotic microangiopathies (TMAs).
OMER: 11.10 (+0.34)
Restless Legs Syndrome Pipeline Market 2016 Review Research
PR Newswire - Mon Apr 11, 7:30AM CDT
New market research titled "Restless Legs Syndrome - Pipeline Review, H1 2016" is a report that provides an overview of the Restless Legs Syndrome's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
OMER: 11.10 (+0.34)
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 2.35 (-0.02), OMER: 11.10 (+0.34), ATHX: 1.91 (-0.03), KPTI: 10.62 (-0.48), CUR: 0.25 (-0.02)
